^
Association details:
| Biomarker: | HER-2 positive + PD-L1 expression |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Margenza (margetuximab-cmkb) (HER2 inhibitor) + Zynyz (retifanlimab-dlwr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1379P - Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
Published date:
09/13/2021
Excerpt:
MAHOGANY is a 2-cohort study in unresectable metastatic/locally advanced GEA. Cohort A (100 pt single arm) will determine safety/efficacy of Q3W M 15 mg/kg plus R 375 mg in HER2 3+, PD-L1+ (CPS ≥1)...Of these 43, 37 have reached first tumor reassessment, with 1 confirmed complete response, 11 confirmed partial responses...
Trial ID:
